Literature DB >> 29103154

Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease.

Justin N Weilnau1, Michael A Carcella1, Kristin M Miner1, Tarun N Bhatia1, Daniel F Hutchison1, Deepti B Pant1, Negin Nouraei1, Rehana K Leak2.   

Abstract

Dopamine loss and motor deficits in Parkinson's disease typically commence unilaterally and remain asymmetric for many years, raising the possibility that endogenous defenses slow the cross-hemispheric transmission of pathology. It is well-established that the biological response to subtoxic stress prepares cells to survive subsequent toxic challenges, a phenomenon known as preconditioning, tolerance, or stress adaptation. Here we demonstrate that unilateral striatal infusions of the oxidative toxicant 6-hydroxydopamine (6-OHDA) precondition the contralateral nigrostriatal pathway against the toxicity of a second 6-OHDA infusion in the opposite hemisphere. 6-OHDA-induced loss of dopaminergic terminals in the contralateral striatum was ablated by cross-hemispheric preconditioning, as shown by two independent markers of the dopaminergic phenotype, each measured by two blinded observers. Similarly, loss of dopaminergic somata in the contralateral substantia nigra was also abolished, according to two blinded measurements. Motor asymmetries in floor landings, forelimb contacts with a wall, and spontaneous turning behavior were consistent with these histological observations. Unilateral 6-OHDA infusions increased phosphorylation of the kinase ERK2 and expression of the antioxidant enzyme CuZn superoxide dismutase in both striata, consistent with our previous mechanistic work showing that these two proteins mediate preconditioning in dopaminergic cells. These findings support the existence of cross-hemispheric preconditioning in Parkinson's disease and suggest that dopaminergic neurons mount impressive natural defenses, despite their reputation as being vulnerable to oxidative injury. If these results generalize to humans, Parkinson's pathology may progress slowly and asymmetrically because exposure to a disease-precipitating insult induces bilateral upregulation of endogenous defenses and elicits cross-hemispheric preconditioning.

Entities:  

Keywords:  Adaptation; Basal ganglia; Dopamine; Hormesis; Neurodegeneration; Parkinson’s disease; Preconditioning; Tolerance

Mesh:

Substances:

Year:  2017        PMID: 29103154     DOI: 10.1007/s00429-017-1552-6

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  5 in total

1.  The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.

Authors:  Vishakh Iyer; Kala Venkiteswaran; Sandip Savaliya; Christopher A Lieu; Erin Handly; Timothy P Gilmour; Allen R Kunselman; Thyagarajan Subramanian
Journal:  Neurobiol Dis       Date:  2021-08-27       Impact factor: 5.996

2.  Conditioning Against the Pathology of Parkinson's disease.

Authors:  Rehana K Leak
Journal:  Cond Med       Date:  2018-04-28

3.  Proenkephalin Derived Peptides Are Involved in the Modulation of Mitochondrial Respiratory Control During Epileptogenesis.

Authors:  Johannes Burtscher; Camilla Bean; Luca Zangrandi; Iwona Kmiec; Alexandra Agostinho; Luca Scorrano; Erich Gnaiger; Christoph Schwarzer
Journal:  Front Mol Neurosci       Date:  2018-09-25       Impact factor: 5.639

Review 4.  Enhancing and Extending Biological Performance and Resilience.

Authors:  Rehana K Leak; Edward J Calabrese; Walter J Kozumbo; Jeffrey M Gidday; Thomas E Johnson; James R Mitchell; C Keith Ozaki; Reinhard Wetzker; Aalt Bast; Regina G Belz; Hans E Bøtker; Sebastian Koch; Mark P Mattson; Roger P Simon; Randy L Jirtle; Melvin E Andersen
Journal:  Dose Response       Date:  2018-08-15       Impact factor: 2.658

5.  Pronounced α-Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala.

Authors:  Johannes Burtscher; Jean-Christophe Copin; Carmen Sandi; Hilal A Lashuel
Journal:  eNeuro       Date:  2020-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.